➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Johnson and Johnson
Medtronic
Moodys
Colorcon

Last Updated: April 15, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Narlaprevir

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Narlaprevir?

Narlaprevir is an investigational drug.

There have been 7 clinical trials for Narlaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on May 7th 2014.

The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis. The leading clinical trial sponsors are R-Pharm, Almedis, and Merck Sharp & Dohme Corp.

There are two hundred and sixty-six US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Narlaprevir
TitleSponsorPhase
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1AlmedisPhase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1ChromSystemsLabPhase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1Scientific Center EFiSPhase 2

See all Narlaprevir clinical trials

Clinical Trial Summary for Narlaprevir

Top disease conditions for Narlaprevir
Top clinical trial sponsors for Narlaprevir

See all Narlaprevir clinical trials

US Patents for Narlaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Narlaprevir   Start Trial 1',4'-thio nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (Cambridge, MA)   Start Trial
Narlaprevir   Start Trial Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer Cocrystal Pharma, Inc. (Tucker, GA) Emory University (Atlanta, GA)   Start Trial
Narlaprevir   Start Trial Benzimidazole derivatives Enanta Pharmaceuticals, Inc. (Watertown, MA)   Start Trial
Narlaprevir   Start Trial Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Start Trial
Narlaprevir   Start Trial Anti-viral compounds AbbVie Inc. (North Chicago, IL)   Start Trial
Narlaprevir   Start Trial Anti-viral compounds AbbVie Inc. (North Chicago, IL)   Start Trial
Narlaprevir   Start Trial Combination formulation of two antiviral compounds Gilead Pharmasset LLC (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Narlaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Narlaprevir European Patent Office EP3004130 2033-06-05   Start Trial
Narlaprevir World Intellectual Property Organization (WIPO) WO2014197578 2033-06-05   Start Trial
Narlaprevir Canada CA2984421 2035-05-01   Start Trial
Narlaprevir China CN107709344 2035-05-01   Start Trial
Narlaprevir European Patent Office EP3288957 2035-05-01   Start Trial
Narlaprevir Mexico MX2017013956 2035-05-01   Start Trial
Narlaprevir World Intellectual Property Organization (WIPO) WO2016178876 2035-05-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Johnson and Johnson
Medtronic
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.